when will eli lilly release retatrutide Phase 3 obesity trial results 2026 Lilly's triple agonist, retatrutide, successful

This regenerative effect can support the repair of the gut lining, potentially improving symptoms and enhancing gut health

The researchers, based at Tabriz University of Medical Sciences in Tabriz, Iran, conducted an umbrella meta-analysis using a random-effects model

This high purity ensures superior efficacy, making it an excellent option for therapeutic applications

Microbial metabolites like SCFA and Trp derivatives can activate AhR and its target genes, including IL-6, IL-22, prostaglandin G/H synthase 2 (PTGS2), vascular endothelial growth factor A (VEGFA), and cytochrome P450 1 A1 (CYP1 A1) in the intestine or liver